Release Date: March 27, 2023
BUFFALO, N.Y.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of University at Buffalo biomedical engineering professor Jonathan F. Lovell to its College of Fellows.
Lovell, PhD, is a SUNY Empire Innovation Associate Professor in the Department of Biomedical Engineering, a joint program of the School of Engineering and Applied Sciences and the Jacobs School of Medicine and Biomedical Sciences.
Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top 2% of medical and biological engineers.
Lovell was nominated, reviewed, and elected by peers and members of the College of Fellows “for outstanding contributions to the fields of drug and vaccine delivery, based on development of innovative nanoscale technologies.”
Lovell joined UB in 2012 after receiving a PhD in biomedical engineering from the University at Toronto, a master’s of science from McMaster University, and a bachelor’s degree from the University of Waterloo.
At UB, his lab develops next generation nanoparticles and biosensors with the goal of improving human health. A particular research thrust is creating safer, organic nanoparticles for improved cancer therapy.
In addition to his work at UB, Lovell serves as an adjunct faculty member at Roswell Park Comprehensive Cancer Center. Lovell is a co-founder of POP Biotechnologies, a Buffalo-based startup that commercializes technology created in his UB lab. The company is developing, among other products, EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain antigen on the immunogenic liposomes.
AIMBE inducted Lovell and 140 colleagues who make up the AIMBE College of Fellows Class of 2023 on March 27.